ECO24: Tirzepatide Found Effective for Weight Loss Despite Duration of Obesity

Tirzepatide is a once weekly GIP and GLP-1 receptor agonist while semaglutide was a once weekly GLP-1 receptor agonist

WeightControl.com Interview with:
Giovanna Muscogiuri, MD, PhD
Assistant Professor
Endocrinology Unit
University Federico II
Naples, Italy

WeightControl.com:  What is the background for this study? 

Response: The study was a subgroup analysis of SURMOUNT 1-4 aiming to investigate if tirzepatide was effective in terms of percent body weight change, proportions achieving weight loss targets of 5, 10, 15, 20, and 25% and change in waist circumference in subjects with different duration of obesity.

After Bariatric Surgery, Women Advised to Wait At Least Two Years to Conceive

After bariatric surgery there is a rapid weight loss that may impair an adequate weight gain during pregnancy and may also be associated with nutritional deficiencies

WeightControl.com Interview with:
Dr Ana Carreira and Dr Bárbara Araújo
Department of Endocrinology and Metabolism
Centro Hospitalar e Universitário de Coimbra
Coimbra, Portuga

WeightControl.com:  What is the background for this study? 

Response: Bariatric surgery is increasingly common in women of reproductive age and reduces the risk of obesity-related comorbidities in pregnancy. However, women after bariatric surgery have an increased risk of having a baby who is underweight (small for gestational age, SGA). A shorter bariatric surgery-to-conception interval (BSCI) has been one of the factors associated with a higher risk of SGA neonates, and, as a result, women are generally advised to wait at least 12 months after bariatric surgery before trying to conceive. However, the optimal bariatric surgery-to-conception interval is yet to be determined, and current recommendation differ among scientific societies, with some advocating a minimum of 12months and others 18 or 24 months.